Willda Met 50/500 Tablet is a combination oral antidiabetic medication containing Metformin 500 mg and Vildagliptin 50 mg, indicated for the management of type 2 diabetes mellitus. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, improving insulin sensitivity, and enhancing peripheral glucose uptake, thereby aiding in glycemic control. Vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, enhances the incretin system by preventing the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), resulting in increased insulin secretion and decreased glucagon release in a glucose-dependent manner. The combined action of these agents provides complementary mechanisms to effectively reduce fasting and postprandial blood glucose levels. Willda Met 50/500 is typically prescribed when monotherapy with either agent is insufficient to achieve adequate glycemic control. It is to be used alongside diet and exercise modifications. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, primarily attributable to Metformin. Caution is advised in patients with renal impairment, hepatic dysfunction, or conditions predisposing to lactic acidosis. Regular monitoring of blood glucose and renal function is recommended during therapy. This combination offers a convenient and effective option for optimizing glycemic management in type 2 diabetes patients.